NCT06468423View on ClinicalTrials.gov

Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

NACompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Pateints of β-thalassemia Major With Iron Overload
Interventions
DRUG

Deferasirox (DFX)

Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.

DRUG

Deferoxamine (DFO)

DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.

Trial Locations (1)

59210

Thalassemia Center of Hematology Department, The Children's Hospital & The Institute of Child Health, Multan

All Listed Sponsors
lead

RESnTEC, Institute of Research

OTHER